# Pizarra — PT-pseudo_17f110c9e142 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_17f110c9e142
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.171 ng/mL²
  - PSA velocity: 0.72 ng/mL/yr
  - Prior PSA: 5.3 ng/mL
  - Prostate volume: 40.33 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8314881 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 40 mL. DRE nodus. csPCa 0.83.

Vitals: weight 70 kg, height 177 cm, BMI 22.3, BP 124/70 mmHg, HR 82 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2023).

Chief complaint: Specialist reassessment is requested due to a previous prostate cancer diagnosis coupled with a recent PSA increase to 6.9 ng/mL.

History: A 67-year-old retired warehouse worker initiated evaluation for prostate anomalies in 2024 after an initial PSA spike. Currently married yet residing independently, he relies on his adult son for emergency contact and his daughter for managing correspondence. Moderate lower urinary tract symptoms, notably nocturia and a diminished stream, yield an IPSS score of 17. Daily habits encompass a 20-minute walking routine and moderate alcohol intake averaging 16 units weekly. Recent outpatient screenings for hearing and actinic keratosis remain stable. He explicitly denies unexplained weight loss, skeletal pain, or haematuria, maintaining full independence in daily activities. Status: Ex-smoker (10 pack-yr, quit 2023).

Physical examination: Per rectum: Nodus DRE identifies a discrete, firm mass situated in the right peripheral zone, aligning with a cT2 classification. The remainder of the gland demonstrates symmetrical enlargement without additional abnormalities. Systemic assessment shows normal cardiorespiratory parameters. The individual maintains a well-nourished appearance and demonstrates unassisted mobility.

Patient info: retired warehouse worker; Married; Lives alone.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 16 units / week; exercise Walking 20 min/day; IPSS score: 17/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.42 +/- 0.20   (95% CI 0.08-0.82)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.8 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=6.9, age=67.0, psad=0.171, dre_ord=1.0, vol=40.33, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.72 ng/mL/yr), the specific details of the mpMRI report (beyond PI-RADS 5), or the full laboratory panel, which might provide context for the PSA density or other markers.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.42 +/- 0.20), indicating high uncertainty. This uncertainty could stem from the fact that the prior did not see the rising PSA (6.9 from 5.3) or the high PI-RADS 5 score, which strongly suggest cancer, potentially contradicting the 'NO BIOPSY' suggestion. The 'discuss' tier suggests the panel is ambiguous, but the clinical context (rising PSA, PI-RADS 5) might push the decision towards biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report confirms high-grade features or specific lesion characteristics, it would increase the likelihood of biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the likelihood of biopsy.
  <document> laboratory results (full panel) -> If the lab panel shows markers that significantly elevate risk (e.g., specific tumor markers, though none are listed), it would change the decision.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or follow-up plans that influence the current decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_17f110c9e142", "radiology_report": "Subject: Prostate multiparametric MRI | Date: 03 Feb 2025 | Institution: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)\n\nClinical indication: Specialist reassessment prompted by a PSA increase to 6.9 ng/mL and prior biopsy bucket 'Positive'. Previous imaging yielded a PI-RADS 5 classification.\n\nFINDINGS:\nGlandular volume measures 40.33 mL. Peripheral zone imaging reveals a well-circumscribed, irregular T2-hypointense focus in the right mid-gland, spanning roughly 15 x 12 x 10 mm. Restricted diffusion is pronounced on DWI, mirrored by ADC hypointensity. Dynamic contrast sequences demonstrate focal, early arterial uptake. The transition zone exhibits benign nodular hyperplasia. Seminal vesicles remain clear. Pelvic lymph nodes show no suspicious enlargement. Bone marrow signal is uniform.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right peripheral zone.\nProstate volume 40.33 mL; PSAD 0.171 ng/mL/mL.\ncsPCa predicted probability 0.8314881."}

  **psa_trend**
  {"case_id": "PT-pseudo_17f110c9e142", "psa_trend": [{"date": "Oct 2022", "val": 0.7}, {"date": "Dec 2023", "val": 1.8}, {"date": "Feb 2025", "val": 6.9}]}

  **lab_results**
  {"case_id": "PT-pseudo_17f110c9e142", "laboratory_results": [{"name": "PSA", "val": "6.9 ng/mL", "date": "03 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.15 ng/mL", "date": "03 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "17%", "date": "03 Feb 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.2 g/dL", "date": "03 Feb 2025", "flag": ""}, {"name": "WBC", "val": "5.8 x10^9/L", "date": "03 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "191 x10^9/L", "date": "03 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "103 umol/L", "date": "03 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "03 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "16.7 nmol/L", "date": "03 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "61 U/L", "date": "03 Feb 2025", "flag": ""}, {"name": "LDH", "val": "193 U/L", "date": "03 Feb 2025", "flag": ""}]}

  **previous_notes**
  {"case_id": "PT-pseudo_17f110c9e142", "previous_notes": [{"date": "29 Jun 2024", "author": "Dr. P. van Dijk (GP)", "text": "Initial workup commenced in late 2023 after a PSA reading of 5.3 ng/mL led to a transrectal biopsy, which confirmed Gleason 3+4 malignancy. Ongoing active surveillance has tracked his biomarker trajectory. The latest assay, recorded in February 2025, indicates an upward trend to 6.9 ng/mL, driving this specialist consultation for comprehensive reassessment."}]}

NOT RETRIEVED
  get_family_history - Not called because the retrieval of other documents provided sufficient evidence regarding the clinical picture.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - mpMRI report: PI-RADS 5 lesion in the right peripheral zone with restricted diffusion and early arterial uptake.
  - PSA trend: Rapid rise from 1.8 ng/mL (Dec 2023) to 6.9 ng/mL (Feb 2025).
  - previous_notes: Prior biopsy confirmed Gleason 3+4 malignancy, and the current consultation is for reassessment due to a rising PSA.

  AGAINST sampling this patient now:
  - lab_results: %Free PSA is 17% (which is often a favorable prognostic indicator, though context is needed).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which contradicts the statistical prior suggesting no biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to a high-risk PI-RADS 5 lesion and a concerning PSA velocity, evidenced by the rapid rise from 1.8 ng/mL to 6.9 ng/mL. This decision is driven by the PI-RADS 5 score and the rising PSA, which overrides the statistical prior suggesting deferral. The prior biopsy confirmed prior malignancy, making the current reassessment for progression or change the critical factor.

Variables that carried weight: bx=decisive, age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
